1. RxSight faces a class action lawsuit alleging misleading statements. 2. Shareholders must register by September 22, 2025, for possible recovery. 3. The lawsuit claims RxSight overestimated product demand and sales. 4. Allegations cite serious adoption challenges affecting financial forecasts.
Historical precedents show that class actions often result in declines in company stock prices. For instance, when similar lawsuits were filed against biotech companies, their stocks faced significant downturns due to investor sentiment and uncertainty.
The article discusses a significant legal issue that could affect investor perceptions and stock performance. The details about alleged financial misstatements are critical for shareholders.
The immediate impact is driven by market reactions to news of the lawsuit. Class actions can create negative sentiment quickly, leading to short-term price volatility.
NEW YORK, Sept. 4, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of RxSight, Inc. (NASDAQ:RXST).
Shareholders who purchased shares of RXST during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.
CONTACT US HERE:
https://securitiesclasslaw.com/securities/rxsight-inc-loss-submission-form/?id=164991&from=4
CLASS PERIOD: November 7, 2024 to July 8, 2025
ALLEGATIONS: The complaint alleges that during the class period, Defendants issued materially false and/or misleading statements and/or failed to disclose that: (1) the Company was experiencing "adoption challenges" and/or structural issues resulting in declines in sales and utilization; (2) defendants had overstated the demand for RxSight's products; (3) as a result, RxSight was unlikely to meet its own previously issued financial guidance for fiscal year 2025; and (4) that, as a result of the foregoing, defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.
DEADLINE: September 22, 2025 Shareholders should not delay in registering for this class action. Register your information here: https://securitiesclasslaw.com/securities/rxsight-inc-loss-submission-form/?id=164991&from=4
NEXT STEPS FOR SHAREHOLDERS: Once you register as a shareholder who purchased shares of RXST during the timeframe listed above, you will be enrolled in a portfolio monitoring software to provide you with status updates throughout the lifecycle of the case. The deadline to seek to be a lead plaintiff is September 22, 2025. There is no cost or obligation to you to participate in this case.
WHY GROSS LAW FIRM? The Gross Law Firm is a nationally recognized class action law firm, and our mission is to protect the rights of all investors who have suffered as a result of deceit, fraud, and illegal business practices. The Gross Law Firm is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship. The firm seeks recovery on behalf of investors who incurred losses when false and/or misleading statements or the omission of material information by a company lead to artificial inflation of the company's stock. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
The Gross Law Firm
15 West 38th Street, 12th floor
New York, NY, 10018
Email: dg@securitiesclasslaw.com
Phone: (646) 453-8903
View original content to download multimedia:https://www.prnewswire.com/news-releases/the-gross-law-firm-reminds-shareholders-of-a-lead-plaintiff-deadline-of-september-22-2025-in-rxsight-inc-lawsuit--rxst-302546168.html
SOURCE The Gross Law Firm